Compare Stocks: ALLR, ACRV, RLYB, and ACET

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACET Adicet Bio	$9.18 +1.9%	$8.82	$6.01 ▼ $17.44	$85.94M	1.58	127,215 shs	114,190 shs
ACRV Acrivon Therapeutics	$1.85 +8.8%	$1.88	$1.27 ▼ $3.56	$79.28M	1.92	259,535 shs	477,361 shs
ALLR Allarity Therapeutics	$1.21 +4.3%	$1.29	$0.77 ▼ $1.84	$19.25M	0.56	95,152 shs	185,434 shs
RLYB Rallybio	$17.19 +0.2%	$16.59	$3.67 ▼ $17.57	$91.29M	-0.85	9,313 shs	16,092 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACET Adicet Bio	0.00%	-3.57%	-2.13%	+13.33%	-24.53%
ACRV Acrivon Therapeutics	0.00%	-7.50%	-15.91%	+17.83%	+18.59%
ALLR Allarity Therapeutics	0.00%	-0.82%	-15.38%	-15.38%	-17.69%
RLYB Rallybio	0.00%	+1.84%	+3.55%	+7.64%	+277.97%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACET Adicet Bio	$9.18 +1.9%	$8.82	$6.01 ▼ $17.44	$85.94M	1.58	127,215 shs	114,190 shs
ACRV Acrivon Therapeutics	$1.85 +8.8%	$1.88	$1.27 ▼ $3.56	$79.28M	1.92	259,535 shs	477,361 shs
ALLR Allarity Therapeutics	$1.21 +4.3%	$1.29	$0.77 ▼ $1.84	$19.25M	0.56	95,152 shs	185,434 shs
RLYB Rallybio	$17.19 +0.2%	$16.59	$3.67 ▼ $17.57	$91.29M	-0.85	9,313 shs	16,092 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACET Adicet Bio	0.00%	-3.57%	-2.13%	+13.33%	-24.53%
ACRV Acrivon Therapeutics	0.00%	-7.50%	-15.91%	+17.83%	+18.59%
ALLR Allarity Therapeutics	0.00%	-0.82%	-15.38%	-15.38%	-17.69%
RLYB Rallybio	0.00%	+1.84%	+3.55%	+7.64%	+277.97%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACET Adicet Bio	2.88	Moderate Buy	$46.80	409.80% Upside
ACRV Acrivon Therapeutics	2.50	Moderate Buy	$13.50	629.73% Upside
ALLR Allarity Therapeutics	2.00	Hold	$10.25	747.11% Upside
RLYB Rallybio	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ALLR, ACRV, RLYB, and ACET Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	ACET Adicet Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$27.00
9/11/2026	RLYB Rallybio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
9/2/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/1/2026	ACET Adicet Bio	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	ACET Adicet Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/19/2026	RLYB Rallybio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/11/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/6/2026	ACET Adicet Bio	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$100.00 ➝ $90.00
8/5/2026	RLYB Rallybio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	ALLR Allarity Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/15/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACET Adicet Bio	N/A	N/A	N/A	N/A	$16.62 per share	N/A
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$3.57 per share	N/A
ALLR Allarity Therapeutics	$320K	60.16	N/A	N/A	$0.61 per share	1.98
RLYB Rallybio	$860K	106.14	N/A	N/A	$10.98 per share	1.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACET Adicet Bio	-$116.80M	-$11.45	N/A	N/A	N/A	N/A	-74.90%	-60.87%	11/4/2026 (Estimated)
ACRV Acrivon Therapeutics	-$77.90M	-$1.88	N/A	N/A	N/A	N/A	-70.14%	-61.60%	11/12/2026 (Estimated)
ALLR Allarity Therapeutics	-$11.23M	-$0.78	N/A	N/A	N/A	N/A	-152.77%	-46.50%	11/13/2026 (Estimated)
RLYB Rallybio	-$8.98M	-$4.34	N/A	N/A	N/A	-911.07%	-40.53%	-38.13%	11/5/2026 (Estimated)

Latest ALLR, ACRV, RLYB, and ACET Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ALLR Allarity Therapeutics	-$0.25	-$0.21	+$0.04	-$0.21	N/A	N/A
8/12/2026	Q2 2026	ACRV Acrivon Therapeutics	-$0.5022	-$0.43	+$0.0722	-$0.43	$0.39 million	N/A
8/6/2026	Q2 2026	RLYB Rallybio	-$1.28	-$1.09	+$0.19	$7.53	N/A	N/A
8/5/2026	Q2 2026	ACET Adicet Bio	-$1.69	-$1.99	-$0.30	-$1.99	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACET Adicet Bio	N/A	N/A	N/A	N/A	N/A
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	N/A
RLYB Rallybio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACET Adicet Bio	0.01	6.71	6.71
ACRV Acrivon Therapeutics	N/A	7.99	7.99
ALLR Allarity Therapeutics	N/A	1.11	1.11
RLYB Rallybio	N/A	27.26	27.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACET Adicet Bio	83.89%
ACRV Acrivon Therapeutics	71.62%
ALLR Allarity Therapeutics	11.53%
RLYB Rallybio	90.34%

Insider Ownership

Company	Insider Ownership
ACET Adicet Bio	3.40%
ACRV Acrivon Therapeutics	10.50%
ALLR Allarity Therapeutics	0.16%
RLYB Rallybio	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACET Adicet Bio	102	9.36 million	9.04 million	Optionable
ACRV Acrivon Therapeutics	76	42.85 million	38.35 million	Not Optionable
ALLR Allarity Therapeutics	8	15.91 million	15.89 million	Not Optionable
RLYB Rallybio	40	5.31 million	4.76 million	Not Optionable

ALLR, ACRV, RLYB, and ACET Headlines

Recent News About These Companies

Citadel Advisors LLC Buys New Holdings in Rallybio Corporation $RLYB

September 11, 2026 | marketbeat.com

Rallybio CFO Transition Amid Pending Avenzo Therapeutics Merger

September 9, 2026 | tipranks.com

Nantahala Capital Management LLC Trims Stake in Rallybio Corporation $RLYB

August 29, 2026 | marketbeat.com

Almitas Capital LLC Cuts Stake in Rallybio Corporation $RLYB

August 28, 2026 | marketbeat.com

ADAR1 Capital Management LLC Buys 905,817 Shares of Rallybio Corporation $RLYB

August 26, 2026 | marketbeat.com

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

June 2, 2026 | businesswire.com

Rallybio, Avenzo agree oncology reverse merger backed by $215 million financing

June 2, 2026 | thepharmaletter.comT

RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?

June 1, 2026 | finance.yahoo.com

RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders

June 1, 2026 | businesswire.com

Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

June 1, 2026 | businesswire.com

Rallybio Corporation

May 22, 2026 | edition.cnn.com

Rallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Buys 6,009 Shares

May 21, 2026 | insidertrades.com

Adar1 Capital Management buys $1.11m of Rallybio (RLYB) stock

May 16, 2026 | investing.com

Insider Buying: Rallybio (NASDAQ:RLYB) Major Shareholder Purchases 79,259 Shares of Stock

May 16, 2026 | insidertrades.com

Rallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Acquires 800 Shares

May 14, 2026 | insidertrades.com

Rallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Purchases 35,101 Shares

May 7, 2026 | insidertrades.com

Rallybio Receives Termination Fee After Candid Deal Collapse

May 4, 2026 | tipranks.com

Rallybio CMO Departs Amid Pending Candid Therapeutics Merger

March 31, 2026 | tipranks.com

Candid lists via Rallybio reverse merger, adds $505m financing

March 5, 2026 | thepharmaletter.comT

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

March 4, 2026 | businesswire.com

Rallybio Corp.

March 3, 2026 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR, ACRV, RLYB, and ACET Company Descriptions

Adicet Bio NASDAQ:ACET

$9.18 +0.17 (+1.89%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$9.07 -0.11 (-1.19%)

As of 09/18/2026 07:48 PM Eastern

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Acrivon Therapeutics NASDAQ:ACRV

$1.85 +0.15 (+8.82%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.92 +0.07 (+4.00%)

As of 09/18/2026 07:50 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Allarity Therapeutics NASDAQ:ALLR

$1.21 +0.05 (+4.31%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.20 0.00 (-0.41%)

As of 09/18/2026 07:46 PM Eastern

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Rallybio NASDAQ:RLYB

$17.19 +0.03 (+0.17%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$17.14 -0.05 (-0.29%)

As of 09/18/2026 04:10 PM Eastern

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALLR, ACRV, RLYB, and ACET Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALLR, ACRV, RLYB, and ACET Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALLR, ACRV, RLYB, and ACET Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR, ACRV, RLYB, and ACET Company Descriptions

Adicet Bio NASDAQ:ACET

Acrivon Therapeutics NASDAQ:ACRV

Allarity Therapeutics NASDAQ:ALLR

Rallybio NASDAQ:RLYB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALLR, ACRV, RLYB, and ACET Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALLR, ACRV, RLYB, and ACET Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALLR, ACRV, RLYB, and ACET Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR, ACRV, RLYB, and ACET Company Descriptions

Adicet Bio NASDAQ:ACET

Acrivon Therapeutics NASDAQ:ACRV

Allarity Therapeutics NASDAQ:ALLR

Rallybio NASDAQ:RLYB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools